1 op allopeptide reactivity against the second HLA-DR antigen.

2                                              HLA-DR antigens are associated with both IDDM and period

3 or histocompatibility complex (MHC) class II HLA-DR antigens by lesional keratinocytes was markedly r

4 s a lysosomal cysteine protease and controls HLA-DR-antigen complex presentation through the degradat

5 ism (PCR-SSCP) was used to confirm the extra HLA-DR antigens detected by PCR-SSOP.

6 anscripts was correlated with an increase of HLA-DR antigen expression level.

7 tivity toward their mismatched donor-derived HLA-DR antigens; it was therefore hypothesized that this

8                       There was at least a 1 HLA DR antigen match present between donors and recipien

9 t allorecognition was restricted by a single HLA-DR antigen of the host and directed against one immu

10 o the hypervariable region of the mismatched HLA-DR antigens of the donor (indirect recognition).

11  mismatched for 0 (97%), 1 (90%), or 2 (94%) HLA-DR antigens (P=0.4; log-rank).

12                                      Soluble HLA-DR antigens reflect clinical activity, and they may

13  the hypervariable regions of the mismatched HLA-DR antigen(s) of the donor.

14 nating BB-1-positive Schwann cells expressed HLA-DR antigen, the findings indicate that, in CIDP, Sch

15 ated the number of matched HLA-A, HLA-B, and HLA-DR antigens with graft outcome in 90 patients with P